InVivo Therapeutics to Present at 23rd Annual Piper Jaffray Health Care Conference

InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced CEO Frank Reynolds will present InVivo’s most recent breakthroughs and provide a business update to potential investors during the 23^rd Annual Piper Jaffray Health Care Conference. The invitation-only event is set for Nov. 29-30 at the New York Palace in New York, NY.

Reynolds will present an overview and answer questions about InVivo’s innovative biomaterial scaffold technology on Wednesday, November 30 at 3:30 p.m. The company is currently awaiting FDA approval to move forward with its first human clinical study for acute SCI treatment using its proprietary scaffold to provide structural support to a damaged spinal cord to help prevent paralysis and improve recovery and prognosis for patients. The 10-patient pilot study is expected to begin in early 2012.

Audio from Reynolds’ presentation will be simultaneously webcast live at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NVIV.OB&item_id=4. In addition, both Reynolds and InVivo’s Director of Finance, Sean Moran, will be available throughout the event for one-on-one meetings with investors by appointment only. To schedule a meeting, contact Jillian Jackson at Jillian.E.Jackson@pjc.com or via phone at 612-303-6262 or Sharon Novak at Sharon.A.Novak@pjc.com or via phone at 612-303-6226.

The Piper Jaffray Health Care Conference has a long history as one of the nation’s premiere investment research events for emerging health care technologies. The annual conference brings together more than 275 of the most influential public and private companies to present their forecasts and recent successes in the biotechnology, pharmaceuticals, drug discovery, medical technology, health care services, and medical diagnostics and devices sectors to nearly 1,500 of the top institutional investors, equity portfolio managers and research analysts from around the world. For more information or to register, visit www.piperjaffray.com.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.